About GEn1E
GEn1E is a company based in Palo Alto (United States) founded in 2018 by Ritu Lal. GEn1E has raised $22.67 million across 4 funding rounds from investors including Clear Ventures and Y Combinator. GEn1E offers products and services including GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators. GEn1E operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Nimbus Therapeutics, among others.
- Headquarter Palo Alto, United States
- Founders Ritu Lal
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$22.67 M (USD)
in 4 rounds
-
Latest Funding Round
$5.52 M (USD), Series A
Oct 21, 2025
-
Investors
Clear Ventures
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GEn1E
GEn1E offers a comprehensive portfolio of products and services, including GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators.
Dual signal modulator for treating ARDS and inflammation.
Chronic oral treatment for inflammatory diseases.
Modulators targeting kinase dysregulation in diseases.
People of GEn1E
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of GEn1E
GEn1E has successfully raised a total of $22.67M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.52 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GEn1E
GEn1E has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Clear Ventures and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused early stage VC firm investing in the US, Europe, Asia
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked |
Investor details for GEn1E
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GEn1E
Investment portfolio details for GEn1E
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GEn1E
Detailed financials for GEn1E
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gen1e Comparisons
Peer comparison for GEn1E
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GEn1E
GEn1E operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Nimbus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
Detailed competitors of GEn1E
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gen1e
Complete news archive for GEn1E
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GEn1E
GEn1E was founded in 2018 and raised its 1st funding round 1 year after it was founded.
GEn1E is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Ritu Lal is the current CEO of GEn1E. They have also founded this company.
GEn1E is a funded company, having raised a total of $22.67M across 4 funding rounds to date.
Founded in 2018 and based in Palo Alto, United States, therapeutics for inflammatory and rare diseases are developed through an AI-driven platform. Multiple mechanisms of action in protein targets are addressed to advance novel therapies. The lead candidate, GEn-1124, targets chronic lung conditions, while other molecules remain in research and discovery phases within the biotechnology sector.
GEn1E's top competitors include Moderna, Spark Therapeutics and BridgeBio.
GEn1E offers GEn-1124, p38α:MK2 Dual Signal Modulators, and NextGen ERK 1/2 Modulators.
GEn1E has 2 investors. Key investors include Clear Ventures, and Y Combinator.